Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Orchestra BioMed Holdings (OBIO) Depreciation & Amortization - Total (2024 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Depreciation & Amortization - Total for 2 consecutive years, with $81000.0 as the latest value for Q3 2025.

  • Quarterly Depreciation & Amortization - Total rose 6.58% to $81000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $245000.0 through Dec 2025, down 20.45% year-over-year, with the annual reading at $308000.0 for FY2024, 7.32% up from the prior year.
  • Depreciation & Amortization - Total for Q3 2025 was $81000.0 at Orchestra BioMed Holdings, roughly flat from $81000.0 in the prior quarter.
  • The five-year high for Depreciation & Amortization - Total was $84000.0 in Q4 2024, with the low at $74000.0 in Q1 2024.